Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases

被引：42

作者：

Franchini, Massimo ^{[1
]}

Montagnana, Martina ^{[2
]}

Targher, Giovanni ^{[3
]}

Lippi, Giuseppe ^{[2
]}

机构：

[1] Azienda Osped Verona, Serv Immunoematol & Trasfus, Ctr Emofilia, I-37126 Verona, Italy

[2] Univ Verona, Sez Chim Clin, Dipartimento Sci Morfol Biomed, I-37100 Verona, Italy

[3] Univ Verona, Dipartimento Sci Biomed & Chirurg, Sez Endocrinol & Malattie Metab, I-37100 Verona, Italy

来源：

SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2007年 / 33卷 / 08期

关键词：

ADAMTS-13; von Willebrand factor; thrombotic microangiopathy;

D O I：

10.1055/s-2007-1000365

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Thrombotic thrombocytopenic purpura (TTP) is a severe multisystem thrombotic microangiopathy (TMA). Significant advances have been made in understanding the pathogenesis of TTP since the discovery of ADAMTS-13 ((a) under bar (d) under bar isintegrin (a) under bar nd (m) under bar etalloproteinase with (t) under bar hrombo (s) under bar pondin-1-like domains), the enzyme that regulates the size of von Willebrand factor (VWF) multimers. The inherited forms of TTP are mainly caused by a severe ADAMTS-13 deficiency, yet many aspects of the complex biological relationships between VWF-cleaving metalloproteinase and acquired TMA are still unclear. This latter issue will be critically addressed in this review article. In addition, the published literature evaluating plasma ADAMTS-13 levels in other pathologic conditions different from TMA will also be discussed.

引用

页码：787 / 797

页数：11

共 123 条

[31] Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy [J].

Forman, RB ;

Benkel, SA ;

Novik, Y ;

Tsai, HM .

ACTA HAEMATOLOGICA, 2003, 109 (03) :150-152

[32] Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome [J].

Franchini, Massimo ;

Zaffanello, Marco ;

Veneri, Dino .

THROMBOSIS RESEARCH, 2006, 118 (02) :177-184

[33] The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation [J].

Fuge, R ;

Bird, J M ;

Fraser, A ;

Hart, D ;

Hunt, L ;

Cornish, JM ;

Goulden, N ;

Oakhill, A ;

Pamphilon, DH ;

Steward, CG ;

Marks, DI .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (01) :58-64

[34]

Fung MC, 1999, CANCER-AM CANCER SOC, V85, P2023

[35]

Furlan M, 1999, THROMB HAEMOSTASIS, V81, P8

[36] Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura [J].

Furlan, M ;

Robles, R ;

Solenthaler, M ;

Wassmer, M ;

Sandoz, P ;

Lammle, B .

BLOOD, 1997, 89 (09) :3097-3103

[37] von Willebrand factor: molecular size and functional activity [J].

Furlan, M .

ANNALS OF HEMATOLOGY, 1996, 72 (06) :341-348

[38] The frequency of P475S polymorphism in von Willebrand factor-cleaving protease in the Chinese population and its relevance to arterial thrombotic disorders [J].

Gao, WQ ;

Dai, L ;

Su, J ;

Wang, ZY ;

Ruan, CG .

THROMBOSIS AND HAEMOSTASIS, 2004, 91 (06) :1257-1258

[39] Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus [J].

George, James N. ;

Vesely, Sara K. ;

James, Judith A. .

SOUTHERN MEDICAL JOURNAL, 2007, 100 (05) :512-514

[40] Thrombotic thrombocytopenic purpura [J].

George, JN .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (18) :1927-1935

← 1 2 3 4 5 6 7 8 9 10 →